Halozyme Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M | $-72.2M | $-80.3M |
| Depreciation & Amortization | $11.4M | $10.3M | $11.1M | $6.5M | $3.0M | $3.3M | $4.1M | $2.4M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $76.7M | $71.0M | $73.8M | $43.1M | $0 | $0 | — | — |
| Stock-Based Compensation | $51.6M | $43.4M | $36.6M | $24.4M | $20.8M | $17.2M | $34.8M | $35.7M |
| Net Cash from Operating Activities | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M | $55.5M | $-85.4M | $-49.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $7.0M | $10.7M | $15.3M | $4.8M | $1.5M | $2.5M | $4.0M | $4.7M |
| Business Acquisitions | $726.0M | $0 | $0 | $999.1M | $0 | $0 | — | — |
| Net Cash from Investing Activities | $-545.8M | $-262.7M | $-96.9M | $-487.0M | $-406.3M | $78.4M | $-5.5M | $2.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $342.4M | $250.0M | $402.4M | $200.0M | $350.1M | $150.1M | $200.0M | $0 |
| Net Cash from Financing Activities | $-85.2M | $-218.9M | $-408.0M | $362.4M | $77.9M | $-106.3M | $153.2M | $-63.8M |
| Net Change in Cash | $20.6M | $-2.5M | $-116.3M | $115.5M | $-29.0M | $27.5M | $62.2M | $-110.8M |
| Free Cash Flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M | $53.0M | $-89.5M | $-54.2M |